ORYX GmbH & Co. KG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Private
- Established
- 2007-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.oryx-medicine.com
Clinical Trials
8
Active:3
Completed:5
Trial Phases
1 Phases
Phase 1:6
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 1
6 (100.0%)Parvovirus H-1 (ParvOryx) in Patients With Metastatic Inoperable Pancreatic Cancer
Phase 1
Completed
- Conditions
- Carcinoma, Pancreatic Ductal
- Interventions
- Drug: Parvovirus H-1 (H-1PV)
- First Posted Date
- 2016-01-12
- Last Posted Date
- 2022-11-21
- Lead Sponsor
- Oryx GmbH & Co. KG
- Target Recruit Count
- 7
- Registration Number
- NCT02653313
- Locations
- 🇩🇪
National Center for Tumor Diseases (NCT), Heidelberg, Baden-Württemberg, Germany
Cisplatin-based Chemotherapy Combined With P16_37-63 Peptide Vaccination in Patients With HPV-positive Cancers
Phase 1
Completed
- Conditions
- HPV-induced Cancers
- First Posted Date
- 2015-08-18
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- Oryx GmbH & Co. KG
- Target Recruit Count
- 11
- Registration Number
- NCT02526316
- Locations
- 🇩🇪
Krankenhaus Nordwest, Frankfurt, Germany
Immune Therapy of HPV-induced Cancers
Phase 1
Completed
- Conditions
- HPV-induced Cancers
- First Posted Date
- 2011-10-31
- Last Posted Date
- 2015-06-23
- Lead Sponsor
- Oryx GmbH & Co. KG
- Target Recruit Count
- 26
- Registration Number
- NCT01462838
- Locations
- 🇩🇪
Krankenhaus Nordwest, Frankfurt/Main, Germany
Vaccination Against MSI Colorectal Cancer
Phase 1
Completed
- Conditions
- Colorectal Cancer
- First Posted Date
- 2011-10-27
- Last Posted Date
- 2015-06-23
- Lead Sponsor
- Oryx GmbH & Co. KG
- Target Recruit Count
- 22
- Registration Number
- NCT01461148
- Locations
- 🇩🇪
Krankenhaus Nordwest, Frankfurt/Main, Germany
Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme.
- First Posted Date
- 2011-02-23
- Last Posted Date
- 2022-11-21
- Lead Sponsor
- Oryx GmbH & Co. KG
- Target Recruit Count
- 18
- Registration Number
- NCT01301430
- Locations
- 🇩🇪
Department of Neurosurgery, University Hospital Heidelberg, Heidelberg, Germany
News
No news found